Show simple item record

dc.contributor.authorCoiras, Mayte 
dc.contributor.authorAmbrosioni, Juan
dc.contributor.authorCervantes, Francisco
dc.contributor.authorMiró, José M
dc.contributor.authorAlcamí, José 
dc.date.accessioned2020-06-09T10:53:30Z
dc.date.available2020-06-09T10:53:30Z
dc.date.issued2017-05
dc.identifier.citationExpert Opin Drug Saf. 2017 May;16(5):547-559.es_ES
dc.identifier.issn1474-0338es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/10304
dc.description.abstractINTRODUCTION: Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism. New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection. Areas covered: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection. These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia. The most relevant papers have been selected and commented. Expert opinion: The family of TKIs are directed against the activation of tyrosine kinases from the Src family. Some of these kinases are essential for the activation of CD4 + T cells, the major target of HIV-1. During acute or primary infection the CD4 + T cells are massively activated, which is mostly responsible for the generation of the reservoirs, the spread of the infection and the destruction of activated CD4 + T cells, infected or not. Consequently, we discuss the possibility of using TKIs as adjuvant of the antiretroviral treatment against HIV-1 infection mostly, but not exclusively, during the acute/recent phase.es_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2013-44677-R, SAF2016-78480-R); the Instituto de Salud Carlos III (INT15/00168, ISCIII-FIS PI16CIII/00034); the Spanish AIDS Research Network RD12/0036/0004, RD16CIII/0002/0001-ISCIII-FEDER and the grant RD12/0036/0004; Bristol-Myers Squibb partially financed our study (grant BMS AI471-041). J Ambrosioni developed this work in the frame of a ‘Juan de la Cierva 2012ʹ postdoctoral program, Spanish Ministry of Economy and Competitiveness, Spain. JMM received a personal intensification research grant INT15/00168 in 2016 from Instituto de Salud Carlos III, Madrid, Spain. The European Regional Development Fund (ERDF) ‘A way to build Europe’ also provided funding.es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francis es_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectHIV/AIDSes_ES
dc.subjectT-cell activationes_ES
dc.subjectTyrosine kinase inhibitorses_ES
dc.subjectChronic myeloid leukemiaes_ES
dc.subjectImmunomodulationes_ES
dc.subjectViral reservoirses_ES
dc.subject.meshAnti-HIV Agentses_ES
dc.subject.meshCD4-Positive T-Lymphocyteses_ES
dc.subject.meshChronic Diseasees_ES
dc.subject.meshHIV Infectionses_ES
dc.subject.meshHIV-1es_ES
dc.subject.meshHumanses_ES
dc.subject.meshProtein Kinase Inhibitorses_ES
dc.subject.meshProtein-Tyrosine Kinaseses_ES
dc.titleTyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infectiones_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID28387147es_ES
dc.format.volume16es_ES
dc.format.number5es_ES
dc.format.page547-559es_ES
dc.identifier.doi10.1080/14740338.2017.1313224es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderRed Española de Investigación en SIDA
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)
dc.description.peerreviewedes_ES
dc.identifier.e-issn1744-764Xes_ES
dc.relation.publisherversionhttps://doi.org/10.1080/14740338.2017.1313224es_ES
dc.identifier.journalExpert opinion on drug safetyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2013-44677-Res_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/SAF2016-78480-Res_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ISCIII-FIS PI16CIII/00034es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ RD12/0036/0004es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0002/0001-ISCIII-FEDERes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD12/0036/0004es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/BMS AI471-041es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/INT15/00168es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional